We are monitoring the impact of COVID-19 on Europe Cancer Immunotherapy Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 1338
Share on
Share on

Europe Cancer Immunotherapy Market Research Report – Segmented By Application, Product Type, Mode Of Administration, End Users, Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Industry Analysis, Size, Share, Growth, Trends, Forecast | 2020 to 2025

Pulished: February, 2020
ID: 1338
Pages: 132

Europe Cancer Immunotherapy Market Size (2020 to 2025)

The size of the cancer immunotherapy market in Europe was worth USD 20.92 Billion in 2020 and estimated to reach USD 37.62 Billion by the end of 2025 with a growing potential of 12.45 %.

Increasing prevalence of cancer, changing lifestyle, excess intake of alcohol and smoking, high efficiency of immunotherapy when compared to other treatments, few side effects associated with cancer immunotherapy that reduce the chance of recurrence of cancer are the factors that drive the Europe cancer immunotherapy market. 

A mounting number of cancer patients and rising old people population also drive market growth. The rising commonness of cancer is even driving the European Cancer Immunotherapy Market growth. Numerous healthcare facilities and various national government fund schemes are expected to drive the cancer immunotherapy market in Europe.

Factors like the high cost of immunotherapy treatment and the high reducing rate of the product development cycle are the factors hampering the market growth. The time is also one of the factors that are hampering the regional market boom.

 Increasing opportunities in the existing markets and immunotherapy as an alternative to chemotherapy for the first-line treatment are going to be market drivers in the future. Treatment-Free Survival (TFS) provides an essential opportunity for patients and their families to resume their activities, travel, and generally approach their daily lives free from ongoing cancer treatment.

Another opportunity is patients in their last-stage face the possibility of dying from cancer often value to receive a novel therapy that offers potential for long-term disease control in a small percentage of patients.

The cost of cancer therapy treatment and the availability of very little information are the factors challenging the European market. Another problem is disturbing the immune balance intending to restore the potent anti-tumor response that might induce resistance.

Still, many challenges exist and have to overcome to make it available to the cancer patients who need immune intervention.

This research report has been segmented & sub-segmented into the following categories:

  • By Type of Therapies: Immune System Modulators, Immune Checkpoint Inhibitors and Monoclonal Antibodies
  • By Area of Therapy: Blood Cancer, Prostate Cancer, Melanoma, Breast Cancer, Lung Cancer, Colorectal Cancer & Other Minor Areas
  • By Country: UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe

Europe is the second-largest market share in the global immunotherapy market and holds positive growth along the foreseen period and is supposed to reach a 12.45% growth rate by the end of 2024. This region is presumed to witness a noticeable increase in the upcoming years. In Europe, Germany is the most prominent market which is driving the area and is assumed to experience a growth rate of about 9% in 2024.

The Europe market is becoming apparent rapidly due to the increasing number of cancer patients in this region. The rapid increase of advance treatment facilities paired up with the availability of skilled professionals and support from the government for R&D further boosts the regional business.

Key market participants in the European cancer immunotherapy Market are F. Hoffmann-La Roche Ltd, Amgen, Viralytics, Novartis Pharmaceuticals Corporation, Pfizer, GlaxoSmithKline Pharmaceuticals Limited, AstraZeneca plc, Medivation, Advaxis, Bristol-Myers Squibb, Merck & Co. and Celgene Corp, Immunomedics.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Application                 

                                5.1.1 Introduction           

                                5.1.2 Breast       

                                5.1.3 Lung          

                                5.1.4 Melanoma              

                                5.1.5 Colorectal

                                5.1.6 Head & Neck          

                                5.1.7 Prostate   

                                5.1.8 Others      

                                5.1.9 Y-o-Y Growth Analysis, By Application         

                                5.1.10 Market Attractiveness Analysis, By Application     

                                5.1.11 Market Share Analysis, By Application      

                5.2 Product Type                             

                                5.2.1 Introduction           

                                5.2.2 Monoclonal Antibodies     

                                5.2.3 Checkpoint inhibitors/immune modulators              

                                5.2.4 Therapeutic cancer vaccines            

                                5.2.5 Oncolytic virus immunotherapy     

                                5.2.6 Cytokines

                                5.2.7 Adoptive T cell transfer     

                                5.2.8 Adjuvant Immunotherapy

                                5.2.9 Interferons             

                                5.2.10 Interleukins         

                                5.2.11 BCG         

                                5.2.12 Others   

                                5.2.13 Y-o-Y Growth Analysis, By Product Type   

                                5.2.14 Market Attractiveness Analysis, By Product Type

                                5.2.15 Market Share Analysis, By Product Type  

                5.3 Mode of Administration                        

                                5.3.1 Introduction           

                                5.3.2 Intravenous           

                                5.3.3 Oral            

                                5.3.4 Topical      

                                5.3.5 Intra Vesical           

                                5.3.6 Y-o-Y Growth Analysis, By Mode of Administration

                                5.3.7 Market Attractiveness Analysis, By Mode of Administration              

                                5.3.8 Market Share Analysis, By Mode of Administration

                5.3 End users                    

                                5.3.1 Introduction           

                                5.3.2 Hospitals  

                                5.3.3 Clinics        

                                5.3.4 Y-o-Y Growth Analysis, By End users            

                                5.3.5 Market Attractiveness Analysis, By End users           

                                5.3.6 Market Share Analysis, By End users            

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Application

                                                6.1.3.3 By Product Type

                                                6.1.3.4 By Mode of Administration

                                                6.1.3.5 By End users

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Application

                                                6.1.4.3 By Product Type

                                                6.1.4.4 By Mode of Administration

                                                6.1.4.5 By End users

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Application

                                                6.1.5.3 By Product Type

                                                6.1.5.4 By Mode of Administration

                                                6.1.5.6 By End users

                6.2 U.K                

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 F. Hoffmann-La Roche Ltd                    

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Amgen                         

                8.3 Viralytics                      

                8.4 Novartis Pharmaceuticals Corporation                            

                8.5 Pfizer                            

                8.6 GlaxoSmithKline Pharmaceuticals Limited                     

                8.7 AstraZeneca plc                        

                8.8 Medivation                

                8.9 Advaxis                        

                8.10 Bristol-Myers Squibb                           

                8.11 Merck & Co. and Celgene Corp                        

                8.12 Immunomedics                      

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

 

  1. Europe Cancer Immunotherapy Market By Application, From 2020 to 2025 (USD Billion)
  2. Europe Breast Market By Region, From 2020 to 2025 (USD Billion)
  3. Europe Lung Market By Region, From 2020 to 2025 (USD Billion)
  4. Europe Melanoma Market By Region, From 2020 to 2025 (USD Billion)
  5. Europe Colorectal Market By Region, From 2020 to 2025 (USD Billion)
  6. Europe Head & Neck Market By Region, From 2020 to 2025 (USD Billion)
  7. Europe Prostate Market By Region, From 2020 to 2025 (USD Billion)
  8. Europe Cancer Immunotherapy Market By Product Type, From 2020 to 2025 (USD Billion)
  9. Europe Monoclonal Antibodies Market By Region, From 2020 to 2025 (USD Billion)
  10. Europe Checkpoint inhibitors/immune modulators Market By Region, From 2020 to 2025 (USD Billion)
  11. Europe Therapeutic cancer vaccines Market By Region, From 2020 to 2025 (USD Billion)
  12. Europe Oncolytic virus immunotherapy Market By Region, From 2020 to 2025 (USD Billion)
  13. Europe Cytokines Market By Region, From 2020 to 2025 (USD Billion)
  14. Europe Adoptive T cell Transfer Market By Region, From 2020 to 2025 (USD Billion)
  15. Europe Adjuvant immunotherapy Market By Region, From 2020 to 2025 (USD Billion)
  16. Europe Interferons Market By Region, From 2020 to 2025 (USD Billion)
  17. Europe Interleukins Market By Region, From 2020 to 2025 (USD Billion)
  18. Europe BCG Market By Region, From 2020 to 2025 (USD Billion)
  19. Europe Cancer Immunotherapy Market By Mode of Administration, From 2020 to 2025 (USD Billion)
  20. Europe Intravenous Market By Region, From 2020 to 2025 (USD Billion)
  21. Europe Oral Market By Region, From 2020 to 2025 (USD Billion)
  22. Europe Topical Market By Region, From 2020 to 2025 (USD Billion)
  23. Europe Intravesical Market By Region, From 2020 to 2025 (USD Billion)
  24. Europe Cancer Immunotherapy Market By End users, From 2020 to 2025 (USD Billion)
  25. Europe hospitals Market By Region, From 2020 to 2025 (USD Billion)
  26. Europe Clinics Market By Region, From 2020 to 2025 (USD Billion)
  27. U.K. Cancer Immunotherapy Market By Application, From 2020 to 2025 (USD Billion)
  28. U.K. Cancer Immunotherapy Market By Product Type, From 2020 to 2025 (USD Billion)
  29. U.K. Cancer Immunotherapy Market By Mode of Administration, From 2020 to 2025 (USD Billion)
  30. U.K. Cancer Immunotherapy Market By End users, From 2020 to 2025 (USD Billion)
  31. Germany Cancer Immunotherapy Market By Application, From 2020 to 2025 (USD Billion)
  32. Germany Cancer Immunotherapy Market By Product Type, From 2020 to 2025 (USD Billion)
  33. Germany Cancer Immunotherapy Market By Mode of Administration, From 2020 to 2025 (USD Billion)
  34. Germany Cancer Immunotherapy Market By End users, From 2020 to 2025 (USD Billion)
  35. France Cancer Immunotherapy Market By Application, From 2020 to 2025 (USD Billion)
  36. France Cancer Immunotherapy Market By Product Type, From 2020 to 2025 (USD Billion)
  37. France Cancer Immunotherapy Market By Mode of Administration, From 2020 to 2025 (USD Billion)
  38. France Cancer Immunotherapy Market By End users, From 2020 to 2025 (USD Billion)
  39. Italy Cancer Immunotherapy Market By Application, From 2020 to 2025 (USD Billion)
  40. Italy Cancer Immunotherapy Market By Product Type, From 2020 to 2025 (USD Billion)
  41. Italy Cancer Immunotherapy Market By Mode of Administration, From 2020 to 2025 (USD Billion)
  42. Italy Cancer Immunotherapy Market By End users, From 2020 to 2025 (USD Billion)
  43. Spain Cancer Immunotherapy Market By Application, From 2020 to 2025 (USD Billion)
  44. Spain Cancer Immunotherapy Market By Product Type, From 2020 to 2025 (USD Billion)
  45. Spain Cancer Immunotherapy Market By Mode of Administration, From 2020 to 2025 (USD Billion)
  46. Spain Cancer Immunotherapy Market By End-users, From 2020 to 2025 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample